PHASE II TRIAL OF HIGH-DOSE GEMCITABINE/BUSULFAN/MELPHALAN WITH AUTOLOGOUS STEM-CELL TRANSPLANTATION FOR PRIMARY REFRACTORY OR POOR-RISK RELAPSED HODGKIN’S LYMPHOMA

We conducted a prospective phase 2 trial of gemcitabine, busulfan and melphalan (Gem/Bu/Mel) with autologous stem-cell transplantation (ASCT) in Hodgkin’s lymphoma (HL) patients with primary refractory or poor-risk relapsed disease (extranodal relapse or within 1 year of frontline therapy). The tria...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Biol Blood Marrow Transplant
Main Authors: Nieto, Yago, Thall, Peter F, Ma, Junsheng, Valdez, Benigno C, Ahmed, Sairah, Anderlini, Paolo, Popat, Uday, Jones, Roy B, Shpall, Elizabeth J, Hosing, Chitra, Qazilbash, Muzaffar, Kebriaei, Partow, Alousi, Amin, Timmons, Melissa, Gulbis, Alison, Myers, Alan, Oki, Yasuhiro, Fanale, Michelle, Dabaja, Bouthaina, Pinnix, Chelsea, Milgrom, Sarah, Champlin, Richard, Andersson, Borje S
Format: Artigo
Sprog:Inglês
Udgivet: 2018
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8212703/
https://ncbi.nlm.nih.gov/pubmed/29501779
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2018.02.020
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker